secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071551
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences accelerates PBGENE-DMD, plans IND/CTA in 2025; pauses PBGENE-3243
--------------------------------------------------------------------------------

- PBGENE-DMD is a first-in-class in vivo gene editing approach targeting exons 45-55; up to 60% of DMD patients carry mutations in this hotspot region.
- Preclinical data shows durable functional improvement in a humanized DMD mouse model over 9 months with restored dystrophin expression.
- Precision targets to file IND/CTA for PBGENE-DMD in 2025, with clinical data expected in 2026.
- Company pauses development of PBGENE-3243 (m.3243 mitochondrial disease) to prioritize PBGENE-DMD and HBV; cash runway sufficient for both through Phase 1.
- PBGENE-DMD preclinical data presented at ASGCT Annual Meeting on May 14, 2025; webcast held May 15.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025071551/0000950170-25-071551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025071551/dtil-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer